Nicole J Kim1, David A Jacob2, George N Ioannou1,3, Binu V John4, Shari Rogal5,6, Karine Rozenberg-Ben-Dror7. 1. Division of Gastroenterology, University of Washington, Seattle, Washington. 2. Veteran Affairs Heart of Texas Health Care Network, VISN 17 PBM, Temple, Texas. 3. Division of Gastroenterology, Veteran Affairs Puget Sound Health Care System, Seattle, Washington. 4. Division of Hepatology, Bruce W Carter Veterans Affairs Medical Center, Miami, Florida. 5. Centers for Health Equity Research and Promotion, Veteran Affairs Pittsburgh Healthcare System, Pittsburgh, Pennsylvania. 6. Departments of Medicine and Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania. 7. Veteran Affairs Great Lakes Health Care System, VISN 12 PBM, Westchester, Illinois.
Abstract
INTRODUCTION: We aimed to assess rates and predictors of hepatocellular carcinoma (HCC) screening among patients with cirrhosis. METHODS: We reviewed electronic health records of 11,361 patients with cirrhosis from 11 U.S. Veterans Health Administration facilities for receipt of HCC screening in the 6 months preceding October 1, 2019. RESULTS: Nearly half of the cohort (46%) received HCC screening over a 6-month period. Screening rates and modalities (ultrasound, computed tomography, magnetic resonance imaging, serum alpha fetoprotein) varied by facility. Screening was associated with race/ethnicity, body mass index ≥ 25, cirrhosis etiology, thrombocytopenia, Fibrosis-4 ≥ 3.25, and lower Model for End-Stage Liver Disease-Sodium. DISCUSSION: HCC screening rates varied by facility. Higher risk patients were more likely to receive screening.
INTRODUCTION: We aimed to assess rates and predictors of hepatocellular carcinoma (HCC) screening among patients with cirrhosis. METHODS: We reviewed electronic health records of 11,361 patients with cirrhosis from 11 U.S. Veterans Health Administration facilities for receipt of HCC screening in the 6 months preceding October 1, 2019. RESULTS: Nearly half of the cohort (46%) received HCC screening over a 6-month period. Screening rates and modalities (ultrasound, computed tomography, magnetic resonance imaging, serum alpha fetoprotein) varied by facility. Screening was associated with race/ethnicity, body mass index ≥ 25, cirrhosis etiology, thrombocytopenia, Fibrosis-4 ≥ 3.25, and lower Model for End-Stage Liver Disease-Sodium. DISCUSSION: HCC screening rates varied by facility. Higher risk patients were more likely to receive screening.
Authors: Nicole J Kim; Karine Rozenberg-Ben-Dror; David A Jacob; Kristin Berry; George N Ioannou Journal: Am J Gastroenterol Date: 2022-04-01 Impact factor: 12.045